<SEC-DOCUMENT>0000950170-24-035914.txt : 20240325
<SEC-HEADER>0000950170-24-035914.hdr.sgml : 20240325
<ACCEPTANCE-DATETIME>20240325160738
ACCESSION NUMBER:		0000950170-24-035914
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240325
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240325
DATE AS OF CHANGE:		20240325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROKIDNEY CORP.
		CENTRAL INDEX KEY:			0001850270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981586514
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40560
		FILM NUMBER:		24779271

	BUSINESS ADDRESS:	
		STREET 1:		2000 FRONTIS PLAZA BLVD.
		STREET 2:		SUITE 250
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103
		BUSINESS PHONE:		336-999-7028

	MAIL ADDRESS:	
		STREET 1:		2000 FRONTIS PLAZA BLVD.
		STREET 2:		SUITE 250
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Social Capital Suvretta Holdings Corp. III
		DATE OF NAME CHANGE:	20210310
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>prok-20240325.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-25T16:05:51.6680+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:prok="http://www.prokidney.com/20240325" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_921cf794-8781-433b-ada7-cf4ca1a4fc97" name="dei:EntityCentralIndexKey" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd">0001850270</ix:nonNumeric><ix:nonNumeric id="F_a3c49c0e-e7df-4796-ac09-2c7d9c1ab6c8" name="dei:AmendmentFlag" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="prok-20240325.xsd"/></ix:references><ix:resources><xbrli:context id="C_9dfbed0d-3506-413f-8d92-399a83725edd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-25</xbrli:startDate><xbrli:endDate>2024-03-25</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="min-height:0.5in;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e4e7246-cf3b-4a72-9519-a00cba08062b" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_4bbdb6a2-4241-48a2-b858-bc23779b4214" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 25, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b75860bb-6ef7-45d3-b1d3-22ce55429261" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">PROKIDNEY CORP.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;"/>
    <td style="width:1%;"/>
    <td style="width:20%;"/>
    <td style="width:18%;"/>
    <td style="width:41%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2f77a37c-9a45-438d-bc3e-1e43dd8d2c93" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cayman Islands</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9cd01d42-9633-48f0-8b4b-206cf4c252f0" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-40560</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b9ca0d0d-4104-49a2-b43e-86d7f595be83" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">98-1586514</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4e05742b-65e6-4b34-841a-93fc868a57c5" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2000 Frontis Plaza Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_55161db3-fa2c-4f6c-bf31-38f5370473ee" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_60718d15-c3e1-4d95-bacd-8050c4f068e6" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Winston-Salem</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_36c9e1eb-d026-4cda-b516-33e134aa901a" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">North Carolina</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_de362958-86ef-4588-96c6-06490f78231e" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">27103</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_28a388d1-3fc4-4539-9716-02ecada62fae" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">336</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_07b989d6-4aea-4c95-8582-6f309f3722bf" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">999-7029</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b89651d-43ab-400c-ba46-28fd8479400c" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f88c7153-f6cc-4e50-a76a-29501222403c" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d1e9f36-6fee-4173-b09a-483b1ad41d17" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf87aae5-8be7-4a3f-886e-f26da4bf3953" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;"/>
    <td style="width:1%;"/>
    <td style="width:15%;"/>
    <td style="width:1%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_631d110b-8f48-464b-9a25-29f3aa0bdc1e" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Class A ordinary shares, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_7b28fc72-9b4a-4cb8-85c6-39975509ce61" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PROK</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c41997d4-a49a-4cfd-b84a-8f70459c8345" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_ba8b4a74-b54c-410d-bbdf-bc02e2423958" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_506cba9d-e92b-4659-9f36-67fe76184952" contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 25, 2024, ProKidney Corp. (the &#8220;Company&#8221;) announced the appointment of Ulrich Ernst, Ph.D. as the Company&#8217;s Executive Vice President, Technical Operations effective as of March 25, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Ernst, 62 years old, has over 30 years of experience in the biopharmaceutical industry. Most recently, from May 2019 until February 2024, Dr. Ernst served as Senior Vice President, Technical Operations at Iovance Biotherapeutics, Inc. (Nasdaq: IOVA), a biotechnology company developing tumor infiltrating lymphocyte therapy for people with cancer. Previously, Dr. Ernst served at Amunix Operating Inc., a biotechnology company focused on immuno-oncology therapies for patients with cancer, as Chief Operating Officer from 2017 to April 2019, Senior Vice President, Technical Operations from 2015 to 2016, and Senior Vice President, Manufacturing and Quality Operations from 2013 to 2015. Prior to that, Dr. Ernst held positions as the Senior Vice President, Manufacturing Operations at Cytovance Biologics, Inc. and Site Leader/Vice President, Manufacturing and Manufacturing Services at Alexion Pharmaceuticals, Inc. Dr. Ernst holds a B.S. in Chemical Engineering from the University of Minnesota and a Ph.D. in Chemical Engineering from Lehigh University.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There are no arrangements or understandings between Dr. Ernst and any other person pursuant to which Dr. Ernst was appointed as Executive Vice President, Technical Operations. There are no family relationships between Dr. Ernst and any of the Company&#8217;s existing directors or executive officers, and there are no transactions between Dr. Ernst and the Company that would be reportable under Item 404(a) of Regulation S-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with his appointment to serve as the Company&#8217;s Executive Vice President, Technical Operations, Dr. Ernst and ProKidney, LLC, a Delaware limited company and subsidiary of the Company, entered into an employment agreement, effective as of March 25, 2024 (the &#8220;Employment Agreement&#8221;). Pursuant to the terms of the Employment Agreement, Dr. Ernst&#8217;s annual base salary is $450,000, which may be increased by the Board of Directors or the Talent and Compensation Committee in its discretion. Dr. Ernst is eligible to receive an annual discretionary bonus with an initial target of 40% of his base salary, which will be prorated for the 2024 fiscal year. The Company will also provide relocation assistance to Dr. Ernst in an amount not to exceed $159,000. Dr. Ernst is also eligible to participate in the Company&#8217;s employee health and welfare benefit and retirement programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">     </span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with his entry into the Employment Agreement, Dr. Ernst will receive an option award under the Company&#8217;s 2022 Incentive Equity Plan to purchase 500,000 Class A ordinary shares of the Company (the &#8220;Option Award&#8221;). With respect to 335,000 of such Class A ordinary shares of the Company subject to the Option Award, 25% will vest on the one-year anniversary of the grant date and the remainder in equal quarterly installments over the following three years. With respect to 165,000 Class A ordinary shares of the Company subject to the Option Award, the shares will vest subject to the achievement of performance vesting conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foregoing description of the Employment Agreement is not complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Dr. Ernst also entered into an indemnification agreement in the form the Company has entered into with its other executive officers, which form is filed as Exhibit 10.13 to the Company&#8217;s Current Report on Form 8-K, filed by the Company on July 15, 2022 and is incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:4.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On March 25, 2024, the Company issued a press release announcing the appointment of Dr. Ernst. A copy of the press release is furnished as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:5%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(d)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exhibits.</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exhibits filed as part of this Current Report on Form 8-K are listed in the index to exhibits immediately preceding the signature page to this Current Report on Form 8-K, which index to exhibits is incorporated herein by reference.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:83.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:12.12%;"/>
    <td style="width:4.04%;"/>
    <td style="width:83.84%;"/>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description of Exhibit</span></p></td>
   </tr>
   <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="prok-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Employment Agreement, dated March 25, 2024, by and between ProKidney, LLC and Ulrich Ernst.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="prok-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated March 25, 2024.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:top;padding-bottom:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
  <div style="min-height:0.5in;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;"/>
    <td style="width:44%;"/>
    <td style="width:4%;"/>
    <td style="width:46%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">PROKIDNEY CORP.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">March 25, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Todd Girolamo</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name:	Todd Girolamo<br/>Title:	Chief Legal Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>prok-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">March 25, 2024</font></p>
  <p style="margin-left:0.933%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:68.398%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Ulrich Ernst</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dear Ulrich:</font></p>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:4.2pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;" id="x__this_letter_agreement__this__agreemen"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This letter agreement (this &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) sets forth the terms and conditions of your employment with ProKidney, LLC, a Delaware limited liability company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) as of March 25, 2024 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effective Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). This Agreement will govern your employment with the Company beginning on the Effective Date on the following terms and conditions:</font></div></div>
  <p style="text-indent:6.735%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.009%;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Term:</font></p></td>
    <td style="text-indent:3.8pt;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:3.8pt;text-indent:0;font-size:12pt;margin-top:12.35pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.2in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The term of your employment with the Company will terminate upon delivery to you of notice to such effect, which notice may be given for any or no reason, or upon your earlier resignation, death or disability (as customarily defined by the Company). You acknowledge that no provision contained in this Agreement will entitle you to remain in the employment of the Company or any of its subsidiaries or affiliates or affect the right of the Company to terminate your employment hereunder at any time for any reason, subject to compliance with the termination provisions set forth herein. The period during which you are employed by the Company pursuant to this Agreement shall be referred to as the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Term</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">.&#x201d;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Position:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Technical Operations</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Reporting:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">You will report directly to Bruce Culleton, Chief Executive Officer (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Supervisor</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;).</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Duties and Commitment:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">You shall be employed by the Company on a full-time basis and shall perform such duties and responsibilities on behalf of the Company and its subsidiaries and affiliates (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Company Group</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) as are consistent with your position, and such additional duties and responsibilities on behalf of the Company Group, as may be designated from time to time by the Supervisor.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">You will be required to devote all of your business time to the business and affairs of the Company Group and to the promotion of its interests. Notwithstanding the foregoing, you may engage in other activities, such as personal investments and civic and charitable activities, so long as: (i) such activities do not interfere with your duties and obligations hereunder and (ii) such activities are disclosed in advance to the Board of Directors (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) of ProKidney Corp. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Parent</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;)). In addition, you shall be permitted to serve as a director on any other company&#x2019;s board of directors subject to the prior consent of the Board (which will not be unreasonably withheld).</font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Base Salary:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">During the Term, your annual base salary will be $450,000 per year and will be payable in accordance with the Company&#x2019;s normal payroll practices, less the applicable taxes and elective withholdings. Your base salary may be increased, but not decreased, as determined by the Board or the Compensation Committee of the Board (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Compensation Committee</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;).</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Relocation Assistance:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">You agree to relocate to North Carolina within 12 months following the Effective Date. ProKidney has relocation and transportation partners to assist you with your move. You must use our designated partners to obtain relocation benefits, in accordance with the terms set forth on Schedule B hereto.  The Company will reimburse you for reasonable and customary expenses related to your move that comply with our policy up to an amount not to exceed $159,000, which includes up to $80,000 for moving household goods, up to $75,000 for temporary living costs and up to $4,000 for travel expenses.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Incentive Bonus Eligibility:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">During the Term, you will be eligible for an annual cash bonus pursuant to the Company&#x2019;s annual cash bonus program based on the achievement of performance criteria established by the Compensation Committee for the applicable fiscal year, which may be corporate goals and/or individual criteria. Your initial target bonus will be in an amount equal to 40% of your base salary (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Target Bonus</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;). 90% of your initial Target Bonus will be based on the achievement of corporate goals and 10% of your initial Target Bonus will be based on individual goals. The actual amount of any bonus earned shall be determined by the Compensation Committee based on achievement of the applicable performance criteria after the end of the applicable fiscal year. For purposes of 2024 fiscal year, your actual bonus and any 2025 base salary adjustment will be prorated based on your start date with the Company and actual base salary in effect over that period.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Except as otherwise provided herein, you will be entitled to receive any earned bonus for a fiscal year of the Company if you are employed on the payment date for such bonus.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Long-Term Incentive:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">You will be eligible to receive long-term incentive awards pursuant to the terms of the ProKidney Corp. 2022 Incentive Equity Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Incentive</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Equity Plan</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;) (or any successor plan thereto). Long-term incentive awards will be granted at the discretion of the Compensation Committee and in accordance with market guidelines for your role as approved by the Compensation Committee. Subject to approval by the Compensation Committee, you will receive a one-time stock option award to purchase 500,000 shares of the Company&#x2019;s Class A ordinary shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">New Hire Option Award</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;), which shall be subject to time-based and performance-based vesting terms as set forth on Schedule A hereto.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Future awards will be at the discretion of the Compensation Committee and</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">will be based on your individual performance and the Company&#x2019;s performance during the performance year.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Benefits:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">During your employment with the Company, you will be eligible for participation in employee health and welfare benefits programs, retirement programs, and other fringe benefits maintained by the Company, to the extent consistent with applicable law and the terms of the applicable plans and programs, which may include certain plans and programs available to similarly situated executives of the Company or otherwise applicable to your position from time to time, subject to all plan terms and eligibility requirements. The benefit plans and programs for which you may be eligible are more fully described in the applicable plan summaries and related documents. The Company retains all rights to amend or terminate any such benefit plans and programs, subject to the terms of such employee benefit plans and programs and applicable law, and nothing contained herein shall obligate the Company to continue any benefit plans or programs in the future.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">You will be eligible to receive vacation in accordance with the terms of the Company&#x2019;s Vacation/Paid Time Off &#x201c;PTO&#x201d; policy.</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Business Expenses:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">During the Term, the Company will reimburse you for reasonable business expenses, including travel, entertainment, and other expenses (including a mobile phone and data service) incurred by you in the furtherance of the performance of your duties hereunder, in accordance with the Company&#x2019;s Travel and Entertainment policy as in effect from time to time.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Termination:</font></p></td>
    <td style="text-indent:0.7pt;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:-0.7pt;padding-left:0.7pt;font-size:12pt;margin-top:12.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(a) Upon your termination of employment for any reason, the Company shall pay to you (i) your base salary earned through the date of such termination, (ii) amounts for accrued but unused vacation days in the year of termination and (iii) any unreimbursed business expenses in accordance with the Company&#x2019;s reimbursement policy, not later than thirty (30) business days after the customary documentation regarding such expenses has been received and only to the extent that such expenses are submitted within one year of your termination (collectively, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Accrued Amounts</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;).</font></p><p style="text-indent:-0.7pt;padding-left:0.7pt;font-size:12pt;margin-top:12.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(b) In the event your employment is terminated during the Term by the Company without Cause (as defined below) or by you for Good Reason (as defined below), in addition to the Accrued Amounts, you will be entitled to receive, subject to your timely execution and non-revocation of a Release (as defined below) (i) any earned but unpaid bonus for any prior completed fiscal year, payable when such payments would otherwise be paid, (ii) salary continuation for a period of 9 months following your termination date, payable in accordance with the Company&#x2019;s normal payroll cycle and (iii) continued participation in the Company&#x2019;s group health plan at active employee rates for a period of 9 months following your termination date.</font></p><p style="text-indent:-0.7pt;padding-left:0.7pt;font-size:12pt;margin-top:12.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Notwithstanding the foregoing, upon a termination of your employment by</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="text-indent:0.7pt;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:0.7pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">the Company without Cause or by you for Good Reason within 18 months following a Change in Control (as defined in the Incentive Equity Plan), in addition to the Accrued Amounts, you will be entitled to receive, subject to your timely execution and non-revocation of a Release (i) a lump sum payment equal to the sum of twelve (12) months of your base salary as of immediately prior to the Change in Control and 100% of your then-current Target Bonus, (ii) continued participation in the Company&#x2019;s group health plan at active employee rates for a period of twelve (12) months following your termination date and (iii) full vesting of any equity awards then outstanding held by you (with any performance-based equity awards vesting at &#x201c;target&#x201d; levels). Notwithstanding anything to the contrary set forth in this Agreement and any terms set forth in an award agreement relating to the grant of equity awards to you, the terms of the applicable award agreement shall prevail.</font></p><p style="text-indent:-0.7pt;padding-left:0.7pt;font-size:12pt;margin-top:12.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(c) In the event that your employment is terminated other than for reasons described in subsection (b) above, other than the amounts specified in subsection (a) above, you will not be entitled to receive any payments under this Agreement.</font></p><p style="text-indent:-0.7pt;padding-left:0.7pt;font-size:12pt;margin-top:12.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(d) Payment of any severance payments or benefits pursuant to subsection (b) above is expressly conditioned upon your (i) execution of a general waiver and release of claims substantially in the form attached hereto as Exhibit A (the &#x201c;Release&#x201d;), within fifty (50) days of your termination, and the Release becoming effective upon the expiration of the revocation period (which is 7 days after the Release is executed and returned to the Company) and (ii) continued compliance with this Agreement and the Covenant Agreement (as defined below), provided that in the event your employment is terminated by the Company without Cause, and in accordance with applicable law, the Release shall contain a non-competition covenant in a form substantially similar to the non-competition covenant contained in the Covenant Agreement. If an executed Release is not returned to the Company within fifty (50) days of termination or the Release is revoked by you, the Company shall be relieved of all obligations to pay you severance under this Agreement. The payment described in subsection (b)(ii) will be made on the sixtieth (60th) day following your termination of employment. Any payments described in subsection (b)(i) that would have been paid from the termination date through the sixtieth (60th) day following your termination of employment will be paid in a lump sum on the sixtieth (60th) day following your termination and the remaining installments will commence as of the next payroll period following the sixtieth (60th) day following your termination of employment. Notwithstanding the foregoing, if such sixty (60) day period spans two calendar years, then the foregoing payments shall not commence until the second calendar year. All severance payments shall be subject to legally required tax withholdings and any elective withholdings.</font></p><p style="text-indent:0;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(e) For purposes of this Agreement:</font></p><p style="text-indent:-0.7pt;padding-left:0.7pt;font-size:12pt;margin-top:12.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cause</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d; means (i) any theft, fraud, embezzlement, dishonesty, willful</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="text-indent:0.7pt;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-left:0.7pt;text-indent:0;font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.19791666666666666in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">misconduct, breach of fiduciary duty for personal profit, falsification of any documents or records of the Company or any member of the Company Group, felony or similar act by you (whether or not related to your relationship with the Company); (ii) an act of moral turpitude by you, or any act that causes significant injury to, or is otherwise adversely affecting, the reputation, business, assets, operations or business relationship of the Company (or any member of the Company Group); (iii) any breach by you of any material agreement with or of any material duty of yours to the Company or any member of the Company Group (including breach of confidentiality, non-disclosure, non-use non-competition or non-solicitation covenants towards the Company or any member of the Company Group) or failure to abide by code of conduct or other policies (including, without limitation, policies relating to confidentiality and reasonable workplace conduct); or (iv) any act which constitutes a breach of your fiduciary duty towards the Company or any member of the Company Group including disclosure of confidential or proprietary information thereof or acceptance or solicitation to receive unauthorized or undisclosed benefits, irrespective of their nature, or funds, or promises to receive either, from individuals, consultants or corporate entities that the Company or a Subsidiary does business with; (v) your unauthorized use, misappropriation, destruction, or diversion of any tangible or intangible asset or corporate opportunity of the Company or any member of the Company Group (including, without limitation, the improper use or disclosure of confidential or proprietary information). For the avoidance of doubt, the determination as to whether a termination is for Cause for purposes of this Agreement shall be made in good faith by the Compensation Committee and shall be final and binding on you.</font></p><p style="text-indent:0;font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Good Reason</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d; means the occurrence of any of the following without your consent: (i) a material reduction in your then-current base salary, other than any such reduction that applies generally to similarly situated employees of the Company; (ii) a material diminution in your authority, duties or responsibilities under this Agreement; provided, that you will not have the right to resign for Good Reason pursuant to this provision of the Good Reason definition due to a change in authority, duties or responsibilities solely as a result of Parent or the Company no longer being a publicly traded company; or (iii) a relocation of your principal place of employment by more than 50 miles from its location as of the date hereof. Notwithstanding the foregoing, you will not be deemed to have resigned for Good Reason unless (x) you have provided written notice to the Company of the existence of the circumstances providing grounds for termination for Good Reason within 15 days of the initial existence of such grounds, (y) the Company has not cured such circumstances within 30 days from the date on which such notice is provided and (z) you resign from your employment effective no later than 60 days after the initial existence of such grounds.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Resignation:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effective as of the date of your termination of employment, unless otherwise requested by the Company in writing, you will, automatically and without further action on your part or any other person or entity, resign from all</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">offices, boards of directors (or similar governing bodies) and committees of each member of the Company Group. You agree that you will, at the request of the Company, execute and deliver such documentation as may be required to effect such resignations, and authorize any member of the Company Group to file (or cause to be filed) such documentation, as necessary, with any applicable governmental authority.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cooperation:</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">In consideration for the promises and payments by the Company pursuant to this Agreement, at the request of the Company, for a one-year period following your termination of employment for any reason, you agree to cooperate to the fullest extent possible with respect to matters involving any member of the Company Group about which you have or may have knowledge, including any such matters which may arise before or after the Term; </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">such cooperation shall not unreasonably interfere with any obligations you may have to your current employer at the time. The Company will reimburse you for any reasonable, properly documented out-of-pocket expenses, including your travel expenses and attorneys&#x2019; fees that you actually incur in connection with such cooperation.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Section 409A:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">  </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All references in this Agreement to your termination of employment shall mean your &#x201c;separation from service&#x201d; within the meaning of Section 409A of the Code and Treasury regulations promulgated thereunder. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and administered in accordance with Section 409A. Any payments under this Agreement that may be excluded from Section 409A either as separation pay due to an involuntary separation from service or as a short-term deferral shall be excluded from Section 409A to the maximum extent possible. In the event the terms of this Agreement would subject you to the imposition of taxes and penalties under Section 409A (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">409A Penalties</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;), the Company and you shall cooperate diligently to amend the terms of this Agreement to avoid such 409A Penalties, to the extent possible; </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">provided </font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">that, for the avoidance of doubt, you shall be solely liable for any 409A Penalties incurred by you. To the extent that any amounts payable in installments under this Agreement are reasonably determined to be &#x201c;nonqualified deferred compensation&#x201d; within the meaning of Section 409A of the Code, then each such installment shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment as permitted under Section 409A of the Code.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Notwithstanding any other provision in this Agreement, if as of the date on which your employment terminates, you are a &#x201c;specified employee&#x201d;, as determined by the Company, then with respect to any amount payable or benefit provided under this Agreement or otherwise that the Company reasonably determines would be nonqualified deferred compensation within the meaning of Section 409A of the Code and that under the terms of this Agreement would be payable prior to the six-month anniversary of your</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">effective date of termination, then if required in order to avoid any penalties under Section 409A of the Code, such payment or benefit shall be delayed until the earlier to occur of (a) the first payroll date following the six-month anniversary of such termination date and (b) the date of your death.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">With respect to any reimbursements under this Agreement, such reimbursement shall be made on or before the last day of your taxable year following the taxable year in which you incurred the expense. The amount of any expenses eligible for reimbursement or the amount of any in-kind benefits provided, as the case may be, under this Agreement during any calendar year shall not affect the amount of expenses eligible for reimbursement or the amount of any in-kind benefits provided during any other calendar year. The right to reimbursement or to any in-kind benefit pursuant to this Agreement shall not be subject to liquidation or exchange for any other benefit.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">You acknowledge and agree that notwithstanding any provision of this Agreement, the Company and its affiliates are not providing you with any tax advice with respect to Section 409A of the Code or otherwise and are not making any guarantees or other assurances of any kind to you with respect to the tax consequences or treatment of any amounts paid or payable to you under this Agreement.</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Section 280G:</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">  </font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">If the present value of your Severance Benefits, either alone or together with other payments which you have the right to receive from the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Benefits</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;), would constitute a &#x201c;parachute payment&#x201d; as defined in Section 280G of the Code, then your Benefits shall be either (i) provided to you in full, or (ii) provided to you only as to such lesser extent that would result in no portion of such Benefits being subject to the excise tax imposed by Section 4999 of the Code (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Excise Tax</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;), whichever of the foregoing amounts, taking into account the applicable federal, state, and local income and employment taxes and the Excise Tax, results in the receipt by you, on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such Benefits may be taxable under the Excise Tax.</font></p><p style="font-size:12pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Unless the Company and you otherwise agree, any determination required under section shall be made in writing in good faith by the Company&#x2019;s independent accounting firm or such other nationally or regionally recognized accounting firm selected by the Company (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Accountants</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x201d;), whose determination shall be conclusive and binding upon you and the Company for all purposes. In the event that a reduction to the Benefits under this section, the reduction shall apply first to the Benefits that are not deferred compensation subject to Section 409A of the Code and you shall be given the choice, subject to approval by the Company, of which of such Benefits to reduce; </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">that </font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">such reduction achieves the result specified in clause (ii) above of this section. If a reduction in the Benefits that are subject to Section 409A of the Code is required, such Benefits shall</font><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.58%;"></td>
    <td style="width:80.42%;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="margin-top:0;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.07569444444444445in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">be reduced pro rata, but with no change in the time at which such Benefits shall be paid. For purposes of making the calculations required by this section, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Code. The Company and you shall furnish to the Accountants such information and documents as the Accountants may reasonably request in order to make a determination under this section. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this section.</font></p></td>
   </tr>
  </table>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;" id="x__as_a_condition_of_your_employment__yo"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">As a condition of your employment, you acknowledge and agree that you will be subject to confidentiality, non-disclosure, non-use, non-competition, non-solicitation or other covenants pursuant to an agreement with the Company or any member of the Company Group (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Covenant Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;). Notwithstanding any provision in this Agreement, the Covenant Agreement or otherwise to the contrary, nothing in this Agreement, the Covenant Agreement or otherwise precludes or otherwise limits your ability to (A) communicate directly with and provide information, including documents, not otherwise protected from disclosure by any applicable law or privilege to the Securities and Exchange Commission (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SEC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or any other federal, state or local governmental agency or commission (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Government Agency</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) or self- regulatory organization regarding possible legal violations, without disclosure to the Company, or (B) disclose information which is required to be disclosed by applicable law, regulation, or order or requirement (including without limitation, by deposition, interrogatory, requests for documents, subpoena, civil investigative demand or similar process) of courts, administrative agencies, the SEC, any Government Agency or self-regulatory organizations, provided that you provide the Company with prior notice of the contemplated disclosure and cooperate with the Company in seeking a protective order or other appropriate protection of such information. The Company may not retaliate against you for any of these activities.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;" id="x__you_represent_that_your_performance_o"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">You represent that your performance of all of the terms of this Agreement and the performance of the services for the Company Group do not and will not breach or conflict with any agreement with a third party, including an agreement not to compete or to keep in confidence any proprietary information of another entity acquired by you in confidence or in trust prior to the date of this Agreement. You agree that you will not enter into any agreement that conflicts with this Agreement at any time prior to the Effective Date or during the term of your employment with the Company.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.849%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;" id="x__all_payments_made_under_this_agreemen"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">All payments made under this Agreement shall be reduced by any tax or other amounts required to be withheld under applicable law.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;" id="x__the_parties_hereby_agree_that_any_sui"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The parties hereby agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement shall only be brought in the Chancery Court of the State of Delaware (or other appropriate state court in the State of Delaware) or the Federal courts located in the State of Delaware and not in any other State or Federal courts located in the United States of America or any court in any other country, and each of the parties hereby consents to the jurisdiction of such courts (and of the appropriate appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.13in;min-height:0.93in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:0.935%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in any such court or that any such suit, action or proceeding which is brought in any such court has been brought in an inconvenient form. The parties hereby agree that process in any such suit, action or proceeding may be served on either party anywhere in the world, whether within or without the jurisdiction of any such court. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;" id="x__this_agreement_shall_be_governed__con"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement shall be governed, construed, interpreted and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the State of Delaware, without reference to the principles of conflicts of law or choice of law of the State of Delaware, or any other jurisdiction, and where applicable, the laws of the United States.</font><font id="x__the_invalidity_or_unenforceability_of"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.84%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.602%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;" id="x__the_terms_of_this_agreement_and_the_c"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The terms of this Agreement and the Covenant Agreement are intended by the parties to be the final expression of their agreement with respect to your employment by the Company and supersede, effective as of the Effective Date, all prior understandings and agreements with respect to your employment by the Company, whether written or oral. For the avoidance of doubt, if the Effective Date does not occur, this Agreement will be void </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ab initio</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.849%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;" id="x__by_signing_this_agreement__you_acknow"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By signing this Agreement, you acknowledge that the terms of this Agreement are confidential and may not be disclosed in any manner or form to any party, other than as required by applicable law (including any public disclosure requirements) or as necessary to enforce the terms of this Agreement or to your spouse, attorney and/or tax advisor (if any), without the prior written approval of the Company. You further acknowledge that you will be bound by the terms and conditions contained in the Company&#x2019;s employee handbook, as it may be amended from time to time to the extent not inconsistent with this Agreement and will, upon request of the Company, sign a copy thereof from time to time.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.849%;font-size:0;margin-top:12.05pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;" id="x0__the_rights_and_benefits_under_this_a"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The rights and benefits under this Agreement are personal to you and such rights and benefits shall not be subject to assignment, alienation or transfer, except to the extent such rights and benefits are lawfully available to your estate or any of your beneficiaries upon your death. The Company may assign this Agreement to any affiliate or subsidiary at any time and shall require any entity which at any time becomes a successor, whether by merger, purchase, or otherwise, or otherwise acquires all or substantially all of the assets, membership interests or business of the Company, to expressly assume this Agreement.</font></div></div>
  <div style="margin-left:0.935%;text-indent:6.849%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;margin-right:1.731%;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:1.4788270327562714%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;" id="x1__this_agreement_may_be_executed_in_se"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement. Signatures delivered by facsimile shall be deemed effective for all purposes.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.741%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">[Signature page follows]</font></p>
  <div style="flex-direction:column;display:flex;min-height:1.06in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.92%;font-size:10pt;margin-top:4.2pt;font-family:Times New Roman;margin-bottom:0;margin-right:5.87%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Please sign and date this Agreement in the space indicated and return it to my attention to evidence your understanding and acceptance of the terms set forth herein.</font></p>
  <p style="margin-left:40.933%;font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Sincerely,</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">						PROKIDNEY</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">						By:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">							</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Bruce Culleton</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">							Name: Bruce Culleton</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">							Position: Chief Executive Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Agreed and Accepted:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">/s/ Ulrich Ernst</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">_______________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Name: Ulrich Ernst</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">Date: March 15, 2024</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>prok-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:0.46in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Arial;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="margin-left:1.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img22993735_0.jpg" alt="img22993735_0.jpg" style="width:192px;height:62px;">&#160;</p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:12.85pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Arial;min-width:fit-content;">ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations</font></p>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:8.8pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.111%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies</font></p>
  <p style="margin-left:0.133%;font-size:10pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:0.111%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Mr. Lucio Tozzi joined in January of 2024 as Senior Vice President of Global Clinical Operations having over 30 years of experience in clinical trial execution</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.5pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">WINSTON-SALEM, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">ProKidney Corp. (Nasdaq: PROK) </font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(&#x201c;ProKidney&#x201d; or the &#x201c;Company&#x201d;), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced two recent strategic appointments enhancing the leadership team&#x2019;s expertise in clinical operations and technical operations, positioning the Company for completion of its Phase 3 program and future commercialization. Dr. Ulrich Ernst, PhD joins the Company today as Executive Vice President of Technical Operations, and Mr. Lucio Tozzi was appointed Senior Vice President of Global Clinical Operations on January 22, 2024. Both Dr. Ernst and Mr. Tozzi and will be joining the ProKidney Executive Leadership Team.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.4pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Dr. Ernst has over 30 years of experience in the biopharmaceutical industry with a focus on process development, manufacturing and facility oversight, and supply chain operations in the cell space. Prior to ProKidney, he led process development, and manufacturing of complex therapeutics, including autologous cell therapies and antibody-drug conjugates. Dr. Ernst was Senior Vice President of Technical Operations at Iovance Biotherapeutics, Chief Operating Officer at Amunix Operating Inc., and Senior Vice President of Manufacturing Operations at Cytovance Biologics. Dr. Ernst earned his PhD in chemical engineering at Lehigh University in Pennsylvania.</font></p>
  <p style="margin-left:0.96%;text-indent:-0.135%;padding-left:0.133%;font-size:10pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">&#x201c;Dr. Ernst&#x2019;s expertise in bringing complex process operations through to commercialization and his track record of gaining manufacturing facility approvals and new market authorizations will be invaluable as we progress our Phase 3 program and prepare for BLA submission,&#x201d; said Dr. Bruce Culleton, Chief Executive Officer of ProKidney.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.45pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Mr. Tozzi also brings over 30 years of experience in international drug development and execution of clinical trials across multiple therapeutic categories. He oversaw design and implementation of over 75 Phase 1-4 clinical studies in more than 65 countries in a variety of clinical indications, including kidney disease. Prior to ProKidney, Mr. Tozzi was Senior Vice President and Head of Clinical Operations at Summit Therapeutics and Rain Oncology, and, prior to that, Vice President of Clinical Operations at Protagonist Therapeutics.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Dr. Culleton continued, &#x201c;Mr. Tozzi&#x2019;s extensive background in clinical trial execution has been and will continue to be integral in the coming months for the enrollment of patients in PROACT 1 and PROACT 2. I am pleased to have these seasoned industry veterans join our Executive Leadership Team. They bring critically important experience that strengthens our ability to execute on our late-stage clinical program and prepare the organization for future commercialization of rilparencel.&#x201d;</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">About ProKidney</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney&#x2019;s lead product candidate, rilparencel (also known as REACT&#174;), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program that launched in January 2022. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">www.prokidney.com</font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">.</font></font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="margin-left:0.973%;text-indent:0.136%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">This press release includes &#x201c;forward-looking statements&#x201d; within the meaning of the &#x201c;safe harbor&#x201d; provisions of the Private Securities Litigation Reform Act of 1995. ProKidney&#x2019;s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as &#x201c;expect,&#x201d; &#x201c;estimate,&#x201d; &#x201c;project,&#x201d; &#x201c;budget,&#x201d; &#x201c;forecast,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;plan,&#x201d; &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;could,&#x201d; &#x201c;should,&#x201d; &#x201c;believes,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential,&#x201d; &#x201c;continue,&#x201d; and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company&#x2019;s expectations with respect to financial results and expected cash runway, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company&#x2019;s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company&#x2019;s products, if approved, the advancement of the Company&#x2019;s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings, updating clinical trial protocols, or achieving other milestones related to the Company&#x2019;s product candidates, and the advancement and funding of the Company&#x2019;s developmental programs generally. Most of these factors are outside of the Company&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:0.46in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:0.973%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.074%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company&#x2019;s Class A ordinary shares on the Nasdaq; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearances or approvals for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company&#x2019;s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company&#x2019;s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company&#x2019;s financial performance; the Company&#x2019;s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of COVID-19 or geo-political conflict such as the war in Ukraine on the Company&#x2019;s business; and other risks and uncertainties included under the heading &#x201c;Risk Factors&#x201d; in the Company&#x2019;s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10pt;font-family:Arial;min-width:fit-content;">Contacts</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:7.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Investors:</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:80.731%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">LifeSci Advisors, LLC</font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:80.731%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Daniel Ferry</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </font></p>
  <p style="margin-left:1.107%;font-size:10pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:80.731%;text-align:left;"><font><font style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Daniel@lifesciadvisors.com</font></font></p>
  <div style="flex-direction:column;display:flex;min-height:0.19in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img22993735_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img22993735_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ ,$# 2(  A$! Q$!_\0
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..R<KJQT*-G<****DH_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>prok-20240325.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-03-25T16:05:52.0889+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.prokidney.com/20240325" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:prok="http://www.prokidney.com/20240325" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="prok-20240325.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140585625431008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 25,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROKIDNEY CORP.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001850270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1586514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2000 Frontis Plaza Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Winston-Salem<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">999-7029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary shares, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PROK<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M4$L! A0#%     @ \(!Y6 =!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #P@'E81<)5">\    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" #P@'E8F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( /" >5BDT(@ND@0  -\1   8
M      " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" #P@'E8GZ ;\+$"  #B#   #0              @ '6#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( /" >5B7BKL<P    !,"   +              "
M ;(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /" >5@ZJJ+G0 $  #P"   /
M              "  9L0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #P
M@'E8)!Z;HJT   #X 0  &@              @ $($@  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #P@'E899!YDAD!  #/ P  $P
M            @ 'M$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   W%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="prok-20240325.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="prok-20240325.htm">prok-20240325.htm</File>
    <File>prok-20240325.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "prok-20240325.htm": {
   "nsprefix": "prok",
   "nsuri": "http://www.prokidney.com/20240325",
   "dts": {
    "inline": {
     "local": [
      "prok-20240325.htm"
     ]
    },
    "schema": {
     "local": [
      "prok-20240325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_9dfbed0d-3506-413f-8d92-399a83725edd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prok-20240325.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9dfbed0d-3506-413f-8d92-399a83725edd",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "prok-20240325.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.prokidney.com/20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-24-035914-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-035914-xbrl.zip
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M"-:"OI-$Q/&0?)()2T+)8G)6=[H#HPP;9#^.R2G6RLFIR$5V*7BC;+-; #H
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MCWJ.B*AE>Q[UG="AFF/Y6N1ZAJDO5QV?I$#)\?_)OHKRK]!$<G7-W(0.UR?
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MNGJB]:?R_)8OX@*WII>;83;QYO6*-^\U@Y0//_QYK]DM>O&'_P=02P,$%
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MH)':_>!NI2-][D>,"P^2&_#C$H/A.F9W$@Z=(PHUK1JJ=.IBXEL-*;RB49H
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MSC&Y=L7X%C'F(>"ZXYFZK[JL1C95C.B"^GKCUC)C5F]1RD$SKL&'"1-O'=T
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ML,>'T-G/7#;<2;.2KCG:;U@2PQO6<]T .\(<'% Q7X$]D*D2KN?AO &E9OE
MH$?M^E5T9#K-TBM.$Z26=)($+'7E28A>ZSE6]0VR9WF&R=^<OLG76/L\3=C$
M#<FQSA$A2PKAB+=F!Z@*UDA9<N2K=9YDTS,&:(YBDXRQ93I2"*C<TZ03UH+E
MN;HG,]E0/"D"%7Y4Q',U9495#A?A)B'SC,(\Z]@-(*AJO*X>UD%!O-U_WR5V
M.]+*C4?$^O9;@@(E&S7=/)G3 P.WJ<U$U&41$)V%$QQLPK$)C3!(NJ AO"OQ
MC3C95&'=);-WS*7/.I=OYST+:FVWHLNZ;J"I:#6D^,@K+M]-9"!:A5GL5=R3
M4N!XST'AAE)=;E )!.R[2B%L*!)HM]S*K;5R:ZW<6D_97K!R:WTG;BT7/V3B
M(H+B!L3/@*]:+Q$6-"V(]!L!G4O*+%%\ J'-K[WH<T&OB3%<5.*&)J57"E!S
M>$8*M,0!L?0'69%54;K\9MTRMI'=W,UGFD5QO7([P_5VH$@"<N3D^Y:Z_K=#
M; G*\':K CWC+_0+]H:ATQS#H@WH"-I4E!4E@MLX''%)))P<#^$)!E\I3Z!S
M"HXNK8'&7=TT.^B6;>V^05^8<,%&\PI>!$!]45D2^5UA=,"JX,C?&$-RV3+2
MZQ;@=!57'"Y(2O=L[9P4U)C_[A?M+X6EZ4:6_&D8;=N<*>\:?HF_R=MA(\5>
M 3%);#$+>:D#<$=!\).>X/N^<^3FCZU#BJUWSNV?=2A"C?#F\"HV33%X_H!>
M(+)003)4<_ \7-PL!Q9HIPZ6.A )&>&:.LPR"Z67Z(;+UW-,Q1>SY'$MJ/<L
MQU/GVDI8U@5'RFK$);32)<Z;TVM"P)'S_Z[95HQ(B?J]7ZK(&3,490@9Y4./
M>V79IV],#OO6[L&U_39;+P>_K/PV3Y!RO=6=1^"2XO4[%VGMI*7/MM;*:YN5
M9[P#*1;$)WXRY@0MSBUE\XXMRAUZ[QMY(&R]LQ'U-OFUFCQ"9V:SPWMLQDR6
M%)?/Z5FJ4%&-)[4S6UIK:E@ZU+].'594.C2S$<_)PD>&64JNT%=N>M%@!$=/
M9ZVT'Z"."9R)1_(A!E-3(QQG?.9]Z0P:A9D@$28D:M9&;]DU<?9,HSL:2 YD
M%@/&0"X9-LA95K6_OQ^PJL?!CQ->Y*FXO.=VW7CG7.*9*9LD3/77BOFQRE"0
MBV,2&:NP(.9(8LP1'"H(')4NPX:I0RF*VOF4^;MO1;6>+QS(;;2G#]6V#:$K
M.ZM<.CV7]D2CUP:>WE"4"A-R>?%C,MJ#AN $6Y?<VQ2)V(V1IIPV#&M<B$+:
M@6GT"6?!= O_OH7-WSBCH<M=YXEP*!;UN(!#D%5K30 ,.%-LK94DJU,A%N?+
M!M5T,=-U)BG=U6 EO@QZ_91.%$^0>0,O@T)R2!$:F[^PM,0XHYSIY@@EU>AJ
M9VP\#B4XXM6)>VRT@J0 Z&#CZ/PP@3BM2ZZ&ZO*131G.9C=CULBP<)Q.DFXY
MS_'N^6FG3)?ME?/$;8TOINZ%>4,[S688"L'&G.88/(E6*KJ=&!Y;6.JY"'RH
M8X ";R:>Y*#RA+U),>D>9)J6@P>&9-FD15Y(,H%M/:0;^H[1J'?_*Z?3O(\P
M1H=2(!!AH<M28QI)%T$)X3CEECF4:TL%:HTFK9&4ZW>&Z=C=./DUF$<%.IEV
M]AHX0\BX\G:MO%TK;]=3MK*LO%W?B;=KJ$4/20VSL4N#Z%%',;)!@/[I2D&8
M6'4,Z/%2]=M*,EH:^ZTZJ-KZR3Z"-+:QHE:*)L&B*1=Y$B*I*S"*%V9%17QJ
MC@2UC;Z+_%)-]> HWNG<,[\MN]72<,@" \=(G'>A]9Z<3J'^,^QIWAK24Q;]
M"N84CA0$](>BUJB&U\N)UY7$;E&'4KF"4!069<O&:1]+$RA>T(O)9/&]D@0S
MT9" VX)HN&1SFH+EW3@OJRLG7Y@8H'T][M ) 4%M=I7/O77<@%V'U0CW7^P\
M"\H1[O9?;C_S:,P@5%G[@QVXP)W<&[3JHEI^93?[NP,@XNZ&[?9W=_>>^9=6
M#WU3\_!U^>9F?WOOY<NMO<&++2 F6WN;V\\:U1F-(*,RU,\V2)Y9LO^??MZR
MI^)!W7+19XT!#W^*5/+WGR[/SD1Y)LYL@X.S?'2&EK4S9S(Y@P\>""P-W1,#
M(.W*.MK-Z3BXQ;XHOWN0)_9^;;&^7K-:7Z]=J\\ZAUS1/M^]B":CL")A4#'F
M*TJ6A=U6[]4(< =GUFXL<"OU[);BJ&GEVM7T9WE<)A]$JY]$&-H8-@PB.]]$
MFY%N,A[LG1($RO!C*E!7ZLI5+-OBU&M'ZY2A76?(W*3.[#;9&13:SQJWSZW\
M-#/+M+A'L;^.O&(3%+DKO )XPWDSPSD5%UP&3YVK5(XM4$"SK LN/44]V8V_
MG.K-E03U^S5HW0'^?#XY?@+(&Y97"<W=^!T;N\-,\[',XCD73G3@?LJ@_L4N
M'RX'+OZ) +Z4Z6C#)$[E&(55C$6F_FSVX[:IP-2*(3I7>6K*$)@*.MXU"NN&
ML3_J];IY(KBPD>VLXQ<]P)@S5T2T>2%[7J87#<YR)EF@:0QNC>,H05<IS"':
MTDW*4(]E["(?$Q1Z1HCEVF4>(0$F.\N!R/6B& D"YDYA9S;,NL5P/3FEQN2N
M\ 20&BR@L,ZE->L"QS"98 6_1,C,&31(5TZ.V=#?PAA[7 M.JVQV_D'AP)!(
MG^\2_>3 ;UWDS-1Q\T5B[SBY5H;)&FHQ>6ST(N4774F/:2M5>36GHH-+;,U4
M2X%]EY"'$Z$:@!*^;M C*&0&("8PUR/(2N8MH*\$)R?"[*1X--(X4\U*:'\X
MH?W%#85V.-JS0NI AC-$9Y;:O3Z)9X\CM/].Q?],B(5KO>>MS'9S&BU-QC".
MG<:;%"'+:9>ES3X+9>8DYQA%JE]FPOET,6FJ9#H":EEY%5M""5W@2@KNK3D/
MZRUXC^*@.B565CHZ)/HBY4RKUZ1AQ-*(FIW%I"D C*^_I&II<#V=K47'+'AC
M47GDJ"IJ#"#V4U-L('2C\]6"DCRT>"Q'4&C?>@ $KA:OH51VMUSC-#PR-@4+
M<=7KWFCY1$=PFI/NZAK>))EW0YGVEY"F6]&EO1>;WSM=VKZI,2%-STQ U!EZ
MU\](3#Q#]#DS&/8XQ@1T"9M0+?+[=X8^>ZWGV.:J51Z,^'"L6@=L-D0RZJF%
M[6MULGL@E*VX[>-C]<X-L1H._8P:+<OR#(L9#.>,R\QX 3W.REH]"E:C(*A7
M%O'*?'+/]8&PV8DIVZDE;DGLS$BE6$4-F9)C5C98F]0';KB<9Z:-!K(-K"]$
MB9<UQ3KE74;E7O?EHB@[N"Y#:EMH.W!B6^Q8 H,\1CW </K/E>9L;V2*O8^Y
M0%M;8F9UF%0(,V#KU763?/ /5J*UQL&5IEUOS/:4W$*<VW!:3?RS4<"7C_9;
MIO O>IJDG*.I+( L&+7>+ME+<4#J@EH6A:[I%AA5^Z1U27;;P^0/X+1EHD*]
M0:]JC10OVT[:P@U^EVEJ84<.A$*BW6?=+(J;(2Y&(XK9+[@I+/H8J/>M*WAP
M-=U;>?*_)4_^<H;U)-C3UU'WQZ#7S0IRMG0"7&>RW'"=LC^DUQ)!55K')TLK
M7D\NYF9*EW%RVERGP>-?YS*K;5N'JZZO?\N9&!&5M.QC^=O6/.51\\9P6'6>
M^M@&CU!X;@8K59+K\$U-G]Y%W$S;BKZ6+.G06505F7OIR'#2ZG"$"YS"D.F+
MO$B3GFW HDL,Y(6UC741V'"C_>CDZ/C7Z,,_HM-?3Z*/1Y].WYY\CGX]^71R
M^H%^O/X]>OOIT\F_/AP?O7[W>_2_1V__!0\<O?\=_GL3';U[%WUZ^\NOIY\C
M>/[TT]NC=Q&\\=^_?8+7WM-C[TY^@0\_?OIP?'+RYNW[7Z*C3V\_X\\/OYWB
MO!\^19].WAV=GKRA(7Y]"Z/_\NGDY)\G[T_Q2US7Z:>C]Y^/CD_??GC_.3K^
M\/[TY)\?^15>XDI.?7PY=??&<JJG955G)&Z=#>49.P=D<H9^WD>24[NU++.R
MGJL&UG/Q'+HTF!9..\N"H6=,7J*YB5NUZ[J_SIG5\0Y9D$P?]7/2SLJ%\J8S
MX-N*;X;HZO8F*<MUSF "?VBW&$?IV@\63A&X>'PJP[MA2N7TR9ZF^6[9@939
M#YPGG@ZCLG.X(HFJYF=Y 9JY!JQV*I[E(Y2='LOO0M3?K9!;I84K-#37TU"\
M\CJ+VV$U$I;]*;HG:!;NZ<A:U?%5-#[W-S?Y19%1I1)=G'I%4A^?I.[=0O4G
MNH*!,0WZ"B=,W\>/IOI?93KOB#@0)//HDHXZ4\#(7&S&HEPLZO^F":L+G%-%
MTU;NY3LWK;J-_!6J_5AC>Q").7RRH\U):#SN<1H'69?)HF:B-TH7YJ,S+Z^U
M$D_*T^V<R$4JTN4]^U37&KDW(H5/8)F/EL7#!!]1U9'[IZU?G],@AMQ<*7\\
M@K^R\C\V47QY0Z(XG)]1%^%LW"2)Y)CD@+Q'(8JOYY%>68MA-T,%;6&ZA42T
MD&&[3Q..;#K*V0@,94RC6<8>?51G3?$1[47T>Q^&(=6-:*JUL+X[M][SPPV\
M((YR75>>M7TH?&/NLLVQQXX(93G+*=;15!?'?3[/"UM9HZ1T:1*,UGN!/LRT
MV5!1FW\6QC&R$]+UCVJ<@!^B.<2>;H9:\\HYMD*'@')4LC )XIW)F:;Z8020
M3H9Y_H7JWBA;"YC*N)K0-O)?HC1O?KI2HVSOI4J89>4Y*5M\EEN<4#KBHB8%
MU/\*0UEG<[:OP@.M^>^?'-Y63/P!*.+^C2CB@.5$@E-)8J')_0[<GX\F)O+"
M.'VV(\TU)'G<P T[RN<VOY:S%3M&650N292(\[J#1ZID9H.EJT)DY0A[5<M+
M;)_=N'8+9\*E 7E$!0LHU+E0J5<C!Z0]&P^IHYWH4WX;FX93G;>9:5O'E=%:
M852\ZB903'R$*4G$.=ZV.[8?"N'JFVLBS;6\.+2#-4;_\:'$"@54-[R.D8#G
MA1-.L3VJ+,8(J5E=Q!-1LJ' FC;"OTSD2&D+"Q@+!_?R<_$VU%6[[.FH\W*B
M9FQQH7@^=/>93M]-,H:LA34"*I-1UDB\%I0E6HETCT/ -@<WHF";+>,AW <T
M'>K>7,F9RLY*^11LA[:F/R^,PRO/C0>63(>"XDB-Y]2WU 2-@%$:0)JDQJCM
M<E*=OB?\CE?NAQ*L;#$;+ =D=.P2) H_Y.HSM2"K\2;J9F8LYHU$3%&OLK44
MIPJW:A<LN$]?X6:\;9F/O>W-X&K$%"YVOS?CZ]77_VNA'*%G5Y=?+/^?Y['\
M=IS,.Z&/>?,'=S W4Y@-J]CRV4)ST]O]6^'[3O]ER EN4RON=I#YF$HLT,DZ
M ^:64@.R1EL65GYH<BQ'HSCD!!\O)-R*#!4>S"M%\03'U85.Y+D.)"4I*#"J
ML4TM1I',C[1E+0P$!J1-H "A]J*"!-"%1[:-[/W%LD,S*LD=XNO#G-%GA:%*
MF)"W"!!/Y'INWM7U7&WNCC=W/42]Z5;_@_Y]_/3A?]Z^>7_R^^I OX\#?3T_
M^(%V^Q_WF;%XTZ4]+Y]'KXL:..4QQG15>79[3\I-UW+6_/<C(<=[T+\.%AS%
MC[#_CSI'\R ZGB@YBDY(,49M\@.U_RY61'^UN=7F?JC-/0P!(GV4M<XC4AQE
M\MABR8]^JO<N\OR6%F@9/2FR\@XJN]R9P/,#B3TL[W2=P^K.?:MGBJ%D!]$_
M10%'NKG3B[8&6]NW,F4; [/99I>->:%Q^YLQ/M]A'<KK&?-?/1_FR?SG_WSU
M?%)-TY__/U!+ P04    " #Q@'E8MA-/N>T/  "L.P  #P   '!R;VLM97@Y
M.5\Q+FAT;>U;:7,;-Q+]GE^!32HINTJD2<FR+$I)K2PKNU[+1R1EL]^VP!F0
MA#4#3# 84<ROW]<-S,%+/J+$26I3Y9(T@P$:?;Q^W4".9S[/OOM"',^43/%3
M''OM,_7=V7]ZAX?]X?&C\"<&/(HCCL<V78C2+S+U[9>Y=%-M1D)6WOY-YX5U
M7AI_5,@TU68Z$D^+VZ,O>=I4W]0?Q;<];XO1H+^OS5&N36^F]'3F\>#Q$SP9
MV]M>J7^A2<;6I<KU\ 13'1?U+!-K/ U1H^&@\$=!DC#G$;^;R%QGB]&5SE4I
M7JNYN+"Y-/7 L?7>YACKU:WOR4Q/S<B1!+0(?5^OD]C,NM%7 _[O:#[37O7*
M0B9J5#C5FSM9A.7F0?ZQS=*CCFQ#R-85Y\1IF?&&YSKUL]%$^UZ"]\K0RF>W
M,SW67@3=TW??'3\J\ _J8S46RYKO96KB1\/^_M[>UT>_@49H>E*(SJ>B=,FW
M7^*7W=W#P[V#O?W_#OKOBNF70F9^X_,H:-CF\' 7KA!M_&27W>*;KX9/!D>T
MOSMV-AP<W+6SX6[_Z?Z*BC]B?PG4KMP]FWSOHTS^UMF7.C5J(4Z,L95)(/M+
M_'6.<%.NG.E"G!2%U<;G^* 4E]XI,_4S91 <XC331B<R$]*DXDHEL_#7FT(Y
MZ;4U9<>+MFIYT!_>[3]/^T\_4L?Q;Q=C>C@<?GU_>F]E7%=S&$#SC;3'8LE6
MQ3]W??%CYG0R$V?.E%Z\@Y)+(4MQ=JN2RNL;)?ZM$R7>.E7J%!\).]FH8S'7
M?B:D2)4JQ%@FUU,'0Z9L$W6+85Z72F@C"F=AWA(#;U1F"S(H#X(&JXE,?.7(
MIE@E45DF8&-L6:O[L>%!__''!LJ?P(BO8,3S*M%67-E??M%L0Y62KO\%G4JW
M(&WN#G8?DUTO$3/6;3#J/S([AD6;8.J8=B9OV"8WRHF]@5@HZ4KZA.VJ%<*5
M%DOJ+SW)CY?L0-9\B.7>BW$'_5]EN&%_</#XZTVH?M]FVV:DGUZ\OKQZ\[IW
M>7)^]FI'O.Z?]G?$*^D0>;O[.\$\#_YQ_N;9F7A]]M/E3R\NSAZ*7D_4VKM'
M;/XXP5ML/K6NZ(L'KV69RI]'XNW%FY</?Y5\GR+.@V^^NMT=#).C1J[P(#T2
M<&O A:@'G-J\D*9Y_7 'Z)0AH9 K9]*KQF$197*J&&^J3+J(.0K.FY0B";.(
MB4VJ$E%EX>@S9_&AN YJ20%L$MCVX/3E<RSB;2H70+20QU+AYU8X13@!]2"B
MU!2?RFXV4V8F34)BD?A9F_.\DGD0__"H7$;1)MAL&Z:$HKZ!YO;%CBALJ>G7
M>HW39E..-Y@I>DLAK2'/VQEM9X^0>NIDSO-.*@"SHL&Y<@D,I'_AR?MB-87L
MX/OG,8]TUXIZ^?C,LL,"K(+<'#-%+4+)GX)JML7'W=T0@7WQS"*+T99".JQ7
M#FO27W.-K#16O,%:G6V(M'OK4)<KF+%_3RCX^'Y1\%U5>CU9_)Y V"H7;O:^
MG$+:'6M;S*3+L3R%)(RH30JY8;?(.3@VR9X;N,7."K%@9Y:)SK1?\.HEJ2;X
M6%D51;9 ?$LLW0FL* @3$E9#'R8G?_.VM?V.X.!--PNQF>%PZ-TN <X.5DNR
MBE&**LK,3BTVMTR&>#H4F9KJT%[JJBGF,N^J*>"E['?\=WY7QM](XZ07+^R-
M)/T_TW99LM.95I-Z,.1[,YE@4D??G.25T;>==R],T@_;WKK^JR5]+,MPNO"M
M%- !UN_N"]Y"%&>F2T8; L29RGDO* Q ?U0PMD<<SF!@\:/1;&L8'8/?*F/*
M188%M/R@R!ST#Y_$P('S0?Y1C\CF_M=UF?_;$=#/R%GJ3-KH?4LR&I.R2=^U
M0]<AT(DACZ19P1 (F;4DPFY"MD1^3*XI6UJ7DH=,90#9Y<AIPA?X[^ E68@'
M Q5">=?*4^#,K(NSEPUF:X/!E1QGBO+07(4,QX)6;F/:@PX+B;Q'B?+9^0D0
M8ISKLL2L.PWM**5.V36?N0K^>EIE2*<8$,.E30EUN&!C#6K<6UZX9WK\&1)#
M)\]FI0U.]=X$0>G?&;8S8I^1<+6P; H1AMRE(@6.DS@+^^=5YC5<MPO%(B&R
M!C<B2/VG"LE"SC$_4D;P64WN3@O)>GX6]V _.M.P][A=L?1 =<79)+>.EI)&
M/-E'.%3&N_A&BAN)W_UB25A@#GY&-M3FAV4"NCDIM5K=G@MH*_\$7Z$U-S$E
MP.AEE>?:BZLN-:;/+BA5OC'D%],%XSW89BT&=HC4MP[\6]: U"#B8*GE\D*?
MBSM]1N0E.*F!A%([4FJEH-H:D1NK=A$9WY:$,YWNRQUE.=.OL5*FI;7U0F0[
MADOXOV/W"_S'Y@S&&#4K&1+IJ3+.9ED>35O G%S44):]>'-R>B6&O$#\8[<O
M7@B *^)&4CF%E6;RAN,.\4)^;$/O(C*\&X7XEO /XML,T]LI-CG-(N"&2)QF
MK@@ZU[3DN]!!KDGU6&PCA@P@QR&O0*B@)D6DDMY0O5B7B;4^-^4)4HAU4_"*
MF-E(2]MJ)]*7TQE]")&R?IU1[LG=5UNPOY.[=YL./&5*Z9PW/()+*@?]J4^/
MC).QK7P+</>BJT%_\"?O+G4 7XH"J@8!KL,63BY]'9^G+Y\W5$P; _;4E#@K
M_0],11EC0C@2NHEPSGTA)YX8/[)@@NAC%T;D4A^K+U9:,H1*U,V@2$FKQ".A
M(H^E"*6=KM^+!YSOKXV=&^)E%V< BF^^&AX\IIX-6"$*/.U*W[.3GO9E[UIS
MDI&T=<7IQA:4,JF07ZF8NML!HA$P**: /D!/86D2S3!1T#X<8"5FU4EE$HY2
M[#S5<JR($C3P!O3@NL+I\IJ44'\D=898[XN+SOX(:*D#!,Q"PE1393CK8:E7
M"GD=X2!.4BYVTICW%N+!Q:N3JX>1:["-=@)G!4SCY_?/3QAWSEZ=B&D%G>+C
M':Y? 76T3>KC6#.U]'M-;->0BT$PD]CH;+E?O#O8!5!_#^QBIJ(-8"R/4@3D
M%C<:Q=12]V_9V^_7O^?S>1]2!RWW@:2;VH[WNV3+.OZ/QEN5!!>92Y?VSBUL
M U>[!!-F0OR!YS6'!WO+9355T$_^VEA]195NP66G4R&8 J7')FI^-XEZS:)>
MRT:O3=E)O:^(\+F2)K:4N@WP4DX4P,>-K6N^HH)9EZ'_.8G-2WU#W?!+$!XB
M39#B'#^F@:)<* I]<9)P]A@>'NYOA'FJS0$LV!0**913DJJ2R0298N)LSFA$
MY"OQ=1&C4%[FU*V*],F^4TG;Q8:R2O5SA?UF2$,+6XER9JL,-;[UI+0%\;)
M&;=KBG 2:@;"^GJ_D8FA0,3[OOC)NK0$:B8S&ENK+0C:UO?-\RCR^ILH_OJ+
M<95.U8;G$!KIL]SPAIIZB2XV+D-\'*EO??E,FO6GL,'Z0Z+YZT\3TNWZXZ#S
M#;M2F88*RTV*8'5O>E-GVDVKAZJC?<.]6(U00O:&-2A4V((/8LEAU#3D3V[I
M1=NR&>=L4;OTV4,A72AFF,@@[7,AJB>+\,UV#^**XFX?BY&[P^%(S#2#W#ZF
MRL[QQW+GK(Z#T,"&H/2())MH0T=!G5"JS\\3HBSP&0ROS!RVK9T9)0UG9V8
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M,S(U+FAT;5!+ 0(4 Q0    ( /& >5AMVD9,N @  .)D   1
M  "  <(8  !P<F]K+3(P,C0P,S(U+GAS9%!+ 0(4 Q0    ( /& >5A$C7Y(
M$"P  +X@ 0 /              "  :DA  !P<F]K+65X,3!?,2YH=&U02P$"
M% ,4    " #Q@'E8MA-/N>T/  "L.P  #P              @ 'F30  <')O
B:RUE>#DY7S$N:'1M4$L%!@     $  0 ^     !>      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>prok-20240325_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prok-20240325.xsd" xlink:type="simple"/>
    <context id="C_9dfbed0d-3506-413f-8d92-399a83725edd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_921cf794-8781-433b-ada7-cf4ca1a4fc97">0001850270</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_a3c49c0e-e7df-4796-ac09-2c7d9c1ab6c8">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_0e4e7246-cf3b-4a72-9519-a00cba08062b">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_4bbdb6a2-4241-48a2-b858-bc23779b4214">2024-03-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_b75860bb-6ef7-45d3-b1d3-22ce55429261">PROKIDNEY CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_2f77a37c-9a45-438d-bc3e-1e43dd8d2c93">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_9cd01d42-9633-48f0-8b4b-206cf4c252f0">001-40560</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_b9ca0d0d-4104-49a2-b43e-86d7f595be83">98-1586514</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_4e05742b-65e6-4b34-841a-93fc868a57c5">2000 Frontis Plaza Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_55161db3-fa2c-4f6c-bf31-38f5370473ee">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_60718d15-c3e1-4d95-bacd-8050c4f068e6">Winston-Salem</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_36c9e1eb-d026-4cda-b516-33e134aa901a">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_de362958-86ef-4588-96c6-06490f78231e">27103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_28a388d1-3fc4-4539-9716-02ecada62fae">336</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_07b989d6-4aea-4c95-8582-6f309f3722bf">999-7029</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_0b89651d-43ab-400c-ba46-28fd8479400c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_f88c7153-f6cc-4e50-a76a-29501222403c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_0d1e9f36-6fee-4173-b09a-483b1ad41d17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_bf87aae5-8be7-4a3f-886e-f26da4bf3953">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_631d110b-8f48-464b-9a25-29f3aa0bdc1e">Class A ordinary shares, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_7b28fc72-9b4a-4cb8-85c6-39975509ce61">PROK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_c41997d4-a49a-4cfd-b84a-8f70459c8345">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_ba8b4a74-b54c-410d-bbdf-bc02e2423958">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_9dfbed0d-3506-413f-8d92-399a83725edd"
      id="F_506cba9d-e92b-4659-9f36-67fe76184952">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
